



PRESS RELEASE

innate pharma®

INNATE PHARMA ANNOUNCES ACHIEVEMENT OF DISCOVERY MILESTONE IN ITS RESEARCH COLLABORATION WITH NOVO NORDISK

Marseille, June 20, 2005

Innate Pharma S.A., a biopharmaceutical company specialized in cancer immuno-therapeutics, today announced the achievement of the first milestone in their collaboration with Novo Nordisk A/S in Denmark. This milestone was achieved as part of the collaboration agreement signed in November 2003 by the two companies on a therapeutic antibody candidate specific for an NK cell receptor. Aside from the research collaboration with Novo Nordisk, Innate Pharma already has two products in Phase 1 clinical trials as well as several other drug candidates in discovery or development in oncology.

This important milestone ends the first stage of the project, during which R&D teams of each company successfully worked together through a comprehensive joint research program. Pending the outcome of the further developments in the program, it will be possible for Innate Pharma to obtain further milestone payments as well as royalties as part of this collaboration.

"Reaching this milestone in the development of our first drug candidate in collaboration with Novo Nordisk is excellent news for Innate," said Hervé Brailly, CEO of Innate Pharma. *"Today, we have several other targets and drug candidates in addition to the one being developed in collaboration with Novo Nordisk, thus Innate Pharma has a significant competitive advantage in a growing and very promising sector of medical research."*

"We are very satisfied with the collaboration with Innate Pharma, and with the performance of our partner." explained Peter Kurtzhals, Senior Vice President, Head of Discovery at Novo Nordisk. *"Novo Nordisk is looking forward to further developments in this project that targets natural killer (NK) cells, a subset of non-conventional lymphocytes involved in immune regulation that exert direct cytotoxicity against a wide range of tumor targets".*

Molecular understanding of this promising field has emerged in the late 90's thanks to the pioneering work of scientists associated with Innate Pharma.

About Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 21,000 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.

For more information, visit www.novonordisk.com.